XWPharma: XWPharma Announces $40 Million Financing and Appoints Leonard Blum as Chief Executive Officer
XWPharma (formerly XW Laboratories), a biopharmaceutical company dedicated to the discovery and development of therapeutics that apply novel platform chemistry to time-regulated neurobiology, today announced it completed a $40 million Series C financing
Read full article »
XWPharma is a biotechnology company that develops and commercializes novel therapeutics for the treatment of neurodegenerative diseases.
Read more